Mankind Pharma's gross margin fell due to inventory accruals and production capacity issues. Revenue growth driven by domestic business and exports. Consumer healthcare business undergoing turnaround with market share gains. Incremental gains expected in chronic therapies. Focus on secondary sales, rural penetration, flagship brands, and market share growth. Strengthening IT systems, strategic focus on user base, and product premiumization.
